The path to rare disease product innovation involves interdependencies between clinical, regulatory, and commercial.

For example, Pear Therapeutics – a digital health pioneer that focused on CBT-based apps for substance use disorders – was ...

Everyone is talking AI these days – and regulators are taking notice. The Artificial Intelligence Act (AI Act), recently ...

Darzi spearheaded an NHS review in 2008 which called for sweeping changes to tackle variations in the quality of care across ...

While advances in cell and gene therapies chip away at the need for bone marrow transplants, the transplantation field ...

Illumina is estimated to have around 80% of the global DNA sequencing market, with Element one of a new generation of rivals ...

Pfizer is advancing on a broad front in its attempt to catch up with Novo Nordisk and Eli Lilly in the obesity drug category ...

The US Senate has come together to pass a bill that aims to prevent pharma companies from filing multiple patents around ...

The only FTC Commissioner who voted against releasing the report – Republican Melissa Holyoak – has also claimed that the ...

Each new breakthrough unlocked further understanding about breast cancer's biological underpinnings and opened the door to ...

We've recently passed the midpoint of 2024, so it's a good time to check in on trends – in this case, trends in the clinical ...

Hudson, meanwhile, joined AbbVie in 2016 from his former role as president and scientific director of the Ontario Institute ...